Literature DB >> 25576668

Negative regulation of TGFβ-induced lens epithelial to mesenchymal transition (EMT) by RTK antagonists.

Guannan Zhao1, Magdalena C Wojciechowski1, Seonah Jee1, Jessica Boros1, John W McAvoy2, Frank J Lovicu3.   

Abstract

An eclectic range of ocular growth factors with differing actions are present within the aqueous and vitreous humors that bathe the lens. Growth factors that exert their actions via receptor tyrosine kinases (RTKs), such as FGF, play a normal regulatory role in lens; whereas other factors, such as TGFβ, can lead to an epithelial to mesenchymal transition (EMT) that underlies several forms of cataract. The respective downstream intracellular signaling pathways of these factors are in turn tightly regulated. One level of negative regulation is thought to be through RTK-antagonists, namely, Sprouty (Spry), Sef and Spred that are all expressed in the lens. In this study, we tested these different negative regulators and compared their ability to block TGFβ-induced EMT in rat lens epithelial cells. Spred expression within the rodent eye was confirmed using RT-PCR, western blotting and immunofluorescence. Rat lens epithelial explants were used to examine the morphological changes associated with TGFβ-induced EMT over 3 days of culture, as well as α-smooth muscle actin (α-sma) immunolabeling. Cells in lens epithelial explants were transfected with either a reporter (EGFP) vector (pLXSG), or with plasmids also coding for different RTK-antagonists (i.e. pLSXG-Spry1, pLSXG-Spry2, pLXSG-Sef, pLSXG-Spred1, pLSXG-Spred2, pLSXG-Spred3), before treating with TGFβ for up to 3 days. The percentages of transfected cells that underwent TGFβ-induced morphological changes consistent with an EMT were determined using cell counts and validated with a paired two-tailed t-test. Explants transfected with pLXSG demonstrated a distinct transition in cell morphology after TGFβ treatment, with ∼60% of the cells undergoing fibrotic-like cell elongation. This percentage was significantly reduced in cells overexpressing the different antagonists, indicative of a block in lens EMT. Of the antagonists tested under these in vitro conditions, Spred1 was the most potent demonstrating the greatest block in TGFβ-induced fibrotic cell elongation/EMT. Through the overexpression of RTK-antagonists in lens epithelial cells we have established a novel role for Spry, Spred and Sef as negative regulators of TGFβ-induced EMT. Further investigations may help us develop a better understanding of the molecular mechanisms involved in maintaining the integrity of the normal lens epithelium, with these antagonists serving as putative therapeutic agents for prevention of EMT, and hence cataractogenesis.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  EMT; Lens pathology; RTK antagonists; Sef; Spred; Spry; TGFβ

Mesh:

Substances:

Year:  2015        PMID: 25576668     DOI: 10.1016/j.exer.2015.01.001

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  13 in total

1.  Prox1 and fibroblast growth factor receptors form a novel regulatory loop controlling lens fiber differentiation and gene expression.

Authors:  Dylan S Audette; Deepti Anand; Tammy So; Troy B Rubenstein; Salil A Lachke; Frank J Lovicu; Melinda K Duncan
Journal:  Development       Date:  2015-12-10       Impact factor: 6.868

Review 2.  Myofibroblast transdifferentiation: The dark force in ocular wound healing and fibrosis.

Authors:  Daisy Y Shu; Frank J Lovicu
Journal:  Prog Retin Eye Res       Date:  2017-08-12       Impact factor: 21.198

3.  ERK1/2 signaling is required for the initiation but not progression of TGFβ-induced lens epithelial to mesenchymal transition (EMT).

Authors:  Magdalena C Wojciechowski; Leila Mahmutovic; Daisy Y Shu; Frank J Lovicu
Journal:  Exp Eye Res       Date:  2017-03-30       Impact factor: 3.467

4.  Negative regulation of lens fiber cell differentiation by RTK antagonists Spry and Spred.

Authors:  Guannan Zhao; Charles G Bailey; Yue Feng; John Rasko; Frank J Lovicu
Journal:  Exp Eye Res       Date:  2018-03-01       Impact factor: 3.467

5.  A linkage between effectual genes in progression of CRC through canonical and non-canonical TGF-β signaling pathways.

Authors:  Marzieh Shirin; Sajedeh Madadi; Noshad Peyravian; Zahra Pezeshkian; Leili Rejali; Masoumeh Hosseini; Afshin Moradi; Binazir Khanabadi; Ghazal Sherkat; Hamid Asadzadeh Aghdaei; Ehsan Nazemalhosseini-Mojarad
Journal:  Med Oncol       Date:  2022-01-29       Impact factor: 3.064

6.  The role of Sprouty1 in the proliferation, differentiation and apoptosis of epidermal keratinocytes.

Authors:  Ping Wang; Yuan Zhou; Jian-Qiang Yang; Lilla Landeck; Min Min; Xi-Bei Chen; Jia-Qi Chen; Wei Li; Sui-Qing Cai; Min Zheng; Xiao-Yong Man
Journal:  Cell Prolif       Date:  2018-07-23       Impact factor: 6.831

7.  Anterior segment dysgenesis correlation with epithelial-mesenchymal transition in Smad4 knockout mice.

Authors:  Jing Li; Yu Qin; Fang-Kun Zhao; Di Wu; Xue-Fei He; Jia Liu; Jiang-Yue Zhao; Jin-Song Zhang
Journal:  Int J Ophthalmol       Date:  2016-07-18       Impact factor: 1.779

8.  Sprouty2 Suppresses Epithelial-Mesenchymal Transition of Human Lens Epithelial Cells through Blockade of Smad2 and ERK1/2 Pathways.

Authors:  Xuhua Tan; Yi Zhu; Chuan Chen; Xiaoyun Chen; Yingyan Qin; Bo Qu; Lixia Luo; Haotian Lin; Mingxing Wu; Weirong Chen; Yizhi Liu
Journal:  PLoS One       Date:  2016-07-14       Impact factor: 3.240

9.  Loss of hSef promotes metastasis through upregulation of EMT in prostate cancer.

Authors:  Satoshi Hori; Karan Wadhwa; Venkat Pisupati; Vincent Zecchini; Antonio Ramos-Montoya; Anne Y Warren; David E Neal; Vincent J Gnanapragasam
Journal:  Int J Cancer       Date:  2017-01-30       Impact factor: 7.396

10.  Systematic analysis of copy number variants of a large cohort of orofacial cleft patients identifies candidate genes for orofacial clefts.

Authors:  Federica Conte; Martin Oti; Jill Dixon; Carine E L Carels; Michele Rubini; Huiqing Zhou
Journal:  Hum Genet       Date:  2015-11-11       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.